Table 2.

Frequent all-causality adverse events (≥10% patients in either treatment group; safety population)

Preferred term n (%)	ONCOS-102 plus chemotherapy (N=20)			Chemotherapy alone (N=11)
	All grade	Grade 3	Grade 4	All grade	Grade 3	Grade 4
Hematological events
Anemia	15 (75.0)	3 (15.0)	0	10 (90.9)	3 (27.3)	0
Lymphopenia	4 (20.0)	1 (5.0)	0	1 (9.1)	0	0
Neutropenia	14 (70.0)	5 (25.0)	3 (15.0)	8 (72.7)	4 (36.4)	1 (9.1)*
Thrombocytopenia	6 (30.0)	3 (15.0)	2 (10.0)†	5 (45.5)	1 (9.1)	0
Non-hematological events
Abdominal pain	3 (15.0)	0	0	0	0	0
Acute kidney injury	3 (15.0)	0	0	1 (9.1)	0	0
ALT increased	1 (5.0)	0	0	2 (18.2)	0	0
Asthenia	17 (85.0)	2 (10.0)	0	7 (63.6)	1 (9.1)	0
Chest pain	6 (30.0)	1 (5.0)	0	3 (27.3)	0	0
Constipation	5 (25.0)	0	0	4 (36.4)	0	0
Cough	6 (30.0)	0	0	1 (9.1)	0	0
C-reactive protein increased	7 (35.0)	0	0	4 (36.4)	0	0
Decreased appetite	7 (35.0)	1 (5.0)	0	6 (54.5)	0	0
Depressed mood	1 (5.0)	0	0	2 (18.2)	0	0
Diarrhea	5 (25.0)	0	0	3 (27.3)	0	0
Dyspnea	3 (15.0)	2 (10.0)	0	2 (18.2)	0	0
Fever	15 (75.0)	1 (5.0)	0	2 (18.2)	0	0
Injection site pain	4 (20.0)	0	0	0	0	0
Musculoskeletal chest pain	5 (25.0)	0	0	0	0	0
Nausea	15 (75.0)	1 (5.0)	0	5 (45.5)	0	0
Non-cardiac chest pain	0	0	0	2 (18.2)	0	0
Pain	4 (20.0)	0	0	0	0	0
Rash	1 (5.0)	0	0	2 (18.2)	0	0
Respiratory tract infection	3 (15.0)	2 (10.0)	0	0	0	0
Tinnitus	1 (5.0)	0	0	2 (18.2)	0	0
Vomiting	10 (50.0)	0	0	2 (18.2)	1 (9.1)	0

*One patient experienced two events of grade 4 neutropenia that were considered related to chemotherapy only.

†An event of grade 4 sepsis was also experienced by a patient with grade 4 thrombocytopenia.

ALT, alanine transaminase.